Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Turning into a Distributed Writer: My Composing Process - 2Vote In favor of Your Number one Savvy Beds
- 3FDA claims on COVID-19 vaccine safety are unsupported by reliable data – and could severely hinder vaccine access
- 4Vote In favor of Your Favored Treat
- 5Courageous Climbing: Trails and Stuff for Outside Lovers
- Instructions to Choose the Best Web based Advertising Degree Program for Your Objectives
- How to watch 'Tell Me Lies' Season 3: Episode release times, streaming info and more
- Antivirus Programming for Exhaustive Security
- Extravagance SUVs for Seniors: Solace, Innovation, and Security
- Figure out How to Pick a Crematorium: Key Contemplations.
- Hungary's 'water guardian' farmers fight back against desertification
- The most effective method to Offset Album Rates with Liquidity Needs
- Figuring out the Justification for Separation: To blame and No-Shortcoming
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
